The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2020

Filed:

Sep. 28, 2017
Applicants:

Xoma (Us) Llc, Berkeley, CA (US);

Musc Foundation for Research Development, Charleston, SC (US);

Inventors:

Marina Roell, Berkeley, CA (US);

Mark Rubinstein, Charleston, SC (US);

Hassan Issafras, Emeryville, CA (US);

Llewelyn Lao, San Francisco, CA (US);

Ou Li, Dublin, CA (US);

Daniel H. Bedinger, Pleasant Hill, CA (US);

Kristin Camfield Lind, Oakland, CA (US);

Agnes Choppin Holmes, Mountain View, CA (US);

Toshihiko Takeuchi, Oakland, CA (US);

Lauren Schwimmer, Alameda, CA (US);

Hoa Giang, Alameda, CA (US);

Amer M. Mirza, San Francisco, CA (US);

Kirk W. Johnson, Moraga, CA (US);

Assignees:

XOMA (US) LLC, Emeryville, CA (US);

MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, Charleston, SC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61P 11/06 (2006.01); A61P 37/06 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); A61K 38/20 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 14/55 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/246 (2013.01); A61K 38/2013 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 11/06 (2018.01); A61P 31/04 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.


Find Patent Forward Citations

Loading…